Skip to main content
. Author manuscript; available in PMC: 2009 Dec 5.
Published in final edited form as: CNS Spectr. 2007 Mar;12(3):211–220. doi: 10.1017/s1092852900020939

TABLE 2.

The Effect of eCB Modulators on the Acquisition and Expression of Conditioned Fear

Authors(Year) Manipulation/Drug Type Drug Name Behavioral Paradigm Observation
Mikics et al (2006)67 CB1 agonist WIN 55, 212-2 Contextual fear conditioning Increased expression of fear
Pamplona & Takahashi (2006)53 CB1 agonist WIN 55,212-2 Contextual fear conditioning No expression effect
Pamplona & Takahashi (2006)53 CB1 agonist WIN 55,212-2 Contextual fear conditioning Decreased fear learning
Mikics et al (2006)67 CB1 antagonist AM251 Contextual fear conditioning Decreased expression of fear
Arenos et al (2006)68 CB1 antagonist AM251 Contextual fear conditioning Decreased expression of fear
Arenos et al (2006)68 CB1 antagonist AM251 Contextual fear conditioning Decreased fear learning
Marsicano et al (2002)64 CB1 antagonist Rimonabant Cued fear conditioning No acquisition effect
Martin et al (2002)65 CB1 gene knockout N/A Active avoidance (after footshock] Increased avoidance
Mikics et al (2006)67 CB1 gene knockout N/A Contextual fear conditioning Decreased acquisition of fear
Mikics et al (2006)67 CB1 gene knockout N/A Contextual fear conditioning Decreased acquisition of fear
Marsicano et al (2002)64 CB1 gene knockout N/A Cued fear conditioning No acquisition effect

eCB=endogenous cannabinoid; CB1=cannabinoid-type 1; N/A=not applicable.

Chhatwal JP, Ressler KJ, CNS Spectr. Vol 12, No 3 2007.